GENE ONLINE|News &
Opinion
Blog

2021-09-16| Asia-PacificCOVID-19

Sinovac to Supply Additional 101,000 COVID-19 Vaccine Doses to Singapore

by Kathy Huang
Share To

On September 15, China’s COVID-19 vaccine producer Sinovac announced it will provide Singapore residents with an additional 101,000 doses of its inactivated COVID-19 vaccine CoronaVac. The vaccines will arrive in Singapore on September 20. 

People can receive the shots at private healthcare institutions. One of them, Livingstone Health group, offers an alternative option for those who cannot receive inactivated vaccines under the National Vaccine Programme.

 

Previous Purchase Plan of Sinovac’s COVID-19 Vaccines

In June, Singapore’s Ministry of Health (MOH) authorized private healthcare institutions to purchase Singapore’s unregistered vaccines under the Special Access Route. Sinovac’s CoronaVac is one of the options on the list, not long after it got WHO’s approval for emergency use on June 1. 

So far, only mRNA vaccines developed by Moderna and Pfizer-BioNTech are under Singapore’s national vaccination program. 

To prevent a drought of stock after second doses and boosters, the MOH has purchased 200,000 Sinovac doses. Of that lot, 170,000 shots are available to the public through private care clinics under the Special Access Route framework. 

“This second delivery of 101,000 CoronaVac doses to Singapore reflects the close working relationships that we have established with essential stakeholders in the country,” said Liu Peicheng, spokesperson for Sinovac. We will continue to pursue such strategic collaborations to help countries move to post-pandemic recovery as soon as possible.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Pfizer’s Q1 2024 Revenue Declines, Offset by Strong Performance of Non-COVID-19 Products
2024-05-03
LATEST
Pfizer’s Q1 2024 Revenue Declines, Offset by Strong Performance of Non-COVID-19 Products
2024-05-03
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
EVENT
Scroll to Top